176 related articles for article (PubMed ID: 23357843)
1. Pharmacokinetic model incorporating mechanism-based inactivation of CYP2D6 can explain both non-linear kinetics and drug interactions of paroxetine.
Mikami A; Ohtani H; Hori S; Sawada Y
Int J Clin Pharmacol Ther; 2013 May; 51(5):374-82. PubMed ID: 23357843
[TBL] [Abstract][Full Text] [Related]
2. [Interactions between metoprolol and antidepressants].
Molden E; Spigset O
Tidsskr Nor Laegeforen; 2011 Sep; 131(18):1777-9. PubMed ID: 21946596
[TBL] [Abstract][Full Text] [Related]
3. In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude.
Venkatakrishnan K; Obach RS
Drug Metab Dispos; 2005 Jun; 33(6):845-52. PubMed ID: 15788540
[TBL] [Abstract][Full Text] [Related]
4. The burden and management of cytochrome P450 2D6 (CYP2D6)-mediated drug-drug interaction (DDI): co-medication of metoprolol and paroxetine or fluoxetine in the elderly.
Bahar MA; Hak E; Bos JHJ; Borgsteede SD; Wilffert B
Pharmacoepidemiol Drug Saf; 2017 Jul; 26(7):752-765. PubMed ID: 28345306
[TBL] [Abstract][Full Text] [Related]
5. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test.
Laine K; Tybring G; Härtter S; Andersson K; Svensson JO; Widén J; Bertilsson L
Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748
[TBL] [Abstract][Full Text] [Related]
7. Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity.
Hamelin BA; Bouayad A; Méthot J; Jobin J; Desgagnés P; Poirier P; Allaire J; Dumesnil J; Turgeon J
Clin Pharmacol Ther; 2000 May; 67(5):466-77. PubMed ID: 10824625
[TBL] [Abstract][Full Text] [Related]
8. Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.
Kuhn UD; Kirsch M; Merkel U; Eberhardt AM; Wenda B; Maurer I; Härtter S; Hiemke C; Volz HP; Balogh A
Int J Clin Pharmacol Ther; 2007 Jan; 45(1):36-46. PubMed ID: 17256449
[TBL] [Abstract][Full Text] [Related]
9. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
Azuma J; Hasunuma T; Kubo M; Miyatake M; Koue T; Higashi K; Fujiwara T; Kitahara S; Katano T; Hara S
Eur J Clin Pharmacol; 2012 Jan; 68(1):29-37. PubMed ID: 21739267
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
[TBL] [Abstract][Full Text] [Related]
11. Toward optimal treatment in women: the effect of sex on metoprolol-diphenhydramine interaction.
Sharma A; Pibarot P; Pilote S; Dumesnil JG; Arsenault M; Bélanger PM; Meibohm B; Hamelin BA
J Clin Pharmacol; 2010 Feb; 50(2):214-25. PubMed ID: 19948945
[TBL] [Abstract][Full Text] [Related]
12. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects.
Yoon YR; Cha IJ; Shon JH; Kim KA; Cha YN; Jang IJ; Park CW; Shin SG; Flockhart DA; Shin JG
Clin Pharmacol Ther; 2000 May; 67(5):567-76. PubMed ID: 10824636
[TBL] [Abstract][Full Text] [Related]
13. Effects of paroxetine on the pharmacokinetics and pharmacodynamics of immediate-release and extended-release metoprolol.
Parker RB; Soberman JE
Pharmacotherapy; 2011 Jul; 31(7):630-41. PubMed ID: 21923449
[TBL] [Abstract][Full Text] [Related]
14. Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine.
Stout SM; Nielsen J; Welage LS; Shea M; Brook R; Kerber K; Bleske BE
J Clin Pharmacol; 2011 Mar; 51(3):389-96. PubMed ID: 20400652
[TBL] [Abstract][Full Text] [Related]
15. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans.
Werner U; Werner D; Rau T; Fromm MF; Hinz B; Brune K
Clin Pharmacol Ther; 2003 Aug; 74(2):130-7. PubMed ID: 12891223
[TBL] [Abstract][Full Text] [Related]
16. Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans.
Min JS; Kim D; Park JB; Heo H; Bae SH; Seo JH; Oh E; Bae SK
Drug Des Devel Ther; 2016; 10():2959-2972. PubMed ID: 27695293
[TBL] [Abstract][Full Text] [Related]
17. The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets.
Berwaerts J; Cleton A; Herben V; van de Vliet I; Chang I; van Hoek P; Eerdekens M
Pharmacopsychiatry; 2009 Jul; 42(4):158-63. PubMed ID: 19585395
[TBL] [Abstract][Full Text] [Related]
18. The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients.
Ismail R; Teh LK
J Clin Pharm Ther; 2006 Feb; 31(1):99-109. PubMed ID: 16476126
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI).
Goryachkina K; Burbello A; Boldueva S; Babak S; Bergman U; Bertilsson L
Eur J Clin Pharmacol; 2008 Mar; 64(3):275-82. PubMed ID: 18043911
[TBL] [Abstract][Full Text] [Related]
20. Profound metoprolol-induced bradycardia precipitated by acetaminophen-propoxyphene.
Marraffa JM; Lang L; Ong G; Lehmann DF
Clin Pharmacol Ther; 2006 Mar; 79(3):282-6. PubMed ID: 16513452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
